The following programs were CME-Certified:
F. Stephen Hodi, Jr., MD - Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACS - Rutgers Cancer Institute of New Jersey
Specifically designed to address the entire unit of care involved in treating cancer patients with immunotherapy, this CME-certified program provided an understanding of basic immunology principles underlying the clinical application of immunotherapy, provided insights into the indications and clinical management of patients receiving tumor immunotherapy, as well as discussed emerging drugs and concepts in the tumor immunotherapy field.
Presented by leading authorities in tumor immunology and cancer immunotherapy, this program summarized central themes in tumor immunotherapy and described the latest research advances and focus on currently approved tumor immunotherapy approaches to facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) management of side effects, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.
Attendees also took advantage of the opportunity for professional networking that promoted collaboration and scientific exchange with experts and clinical oncologists from the surrounding community.
The target audience for these programs included practicing clinical oncologists, those involved in patient care, early career individuals, allied health professionals and patient advocates who wish to learn increasingly sophisticated principles of tumor immunology and immunotherapy, as well as the role of inflammation in cancer development.
Topics included:
To read in-depth session descriptions, click here.
The Advances in Cancer Immunotherapy programs were approved for continuing medical education credits. For full accreditation information, please click on the regional ACI program links above.